LYKALABS vs NEULANDLAB: Stock Comparison

Lyka Labs Limited vs Neuland Laboratories Limited

Live data: 1 July 2026, 4:08 PM IST • Source: NSE and company filings

Neuland Laboratories Limited is the larger company by market capitalisation. Lyka Labs Limited shows a lower P/E and lower leverage, while Neuland Laboratories Limited shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Lyka Labs Limited and Neuland Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, LYKALABS is more favourable on 3 of 13 scored metrics and NEULANDLAB on 10These counts are context-free and are not an overall rating.

Key Differences

Market Cap
NEULANDLAB is the larger company
₹24,223 Cr vs ₹225 Cr
P/E Ratio
LYKALABS has a lower P/E
-20.64x vs 66.9x
P/B Ratio
LYKALABS has a lower P/B
2.24x vs 12.99x
EPS
NEULANDLAB has higher earnings per share
₹293.13 vs ₹-2.81
Dividend Yield
NEULANDLAB has a higher dividend yield
0.06% vs 0%
Revenue Growth (TTM YoY)
NEULANDLAB has faster revenue growth
136.4% vs 0%
EPS Growth (TTM YoY)
NEULANDLAB has faster EPS growth
664.4% vs 0%
Qtr Sales Growth
NEULANDLAB has stronger quarterly sales growth
136% vs 9.7%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricLYKALABSNEULANDLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricLYKALABSNEULANDLAB
Live Price₹74.83₹18,871
Day Change1.19%-0.65%
Volume88,55615,593
52-Week High₹121.44₹20,089
52-Week Low₹44.1₹11,500
Distance from 52W High-38.38%-6.06%

Valuation

MetricLYKALABSNEULANDLAB
Market Cap₹225 Cr₹24,223 Cr
P/E Ratio-20.64x66.9x
P/B Ratio2.24x12.99x
EPS₹-2.81₹293.13
Book Value₹25.87₹1,460.02
Dividend Yield0%0.06%

Growth

MetricLYKALABSNEULANDLAB
Revenue Growth (TTM YoY)0%136.4%
EPS Growth (TTM YoY)0%664.4%
Qtr Sales Growth9.7%136%
Qtr Profit Growth-35.4%665%

Profitability & Leverage

MetricLYKALABSNEULANDLAB
ROE0%21.4%
ROCE9.91%26.6%
Net Margin-7.81%17.99%
Operating Margin-9.43%28.4%
Debt to Equity0x0.16x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricLYKALABSNEULANDLAB
Promoter Holding58.45% 0.29 pp32.62% 0.01 pp
FII Holding0.17% 0.12 pp21.08% 0.62 pp
DII Holding0.66% 0.01 pp16.51% 0.67 pp
Public Holding40.72% 0.16 pp29.79% 1.28 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Lyka Labs Limited and Neuland Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.